

Candida krusei Infection in an Acute Lymphocytic Leukaemia Patient: A Case Report

AROOP MOHANTY¹, SUNEETA MEENA², UTTAM KUMAR NATH³, SUDEEP VANIYATH⁴, NEELAM KAISTHA⁵

ABSTRACT


Although *Candida albicans* remains the predominant species causing Blood Stream Infection (BSI), recent studies have demonstrated an emergence of Non-*albicans Candida* spp (NAC), such as *C. glabrata*, *C. papapsilosis* and *C. krusei*. *Candida krusei* are yeast-like microorganisms which may colonise the human skin, respiratory or gastrointestinal tract but can cause lethal infections especially in immunocompromised patients. Hereby, author's report a case of 10-year-old male with T-cell Acute Lymphocytic Leukaemia (ALL) who reported with fever and non-productive cough caused by *Candida krusei*. Direct gram stain from blood culture and germ tube test was performed. Further, the isolate was initially misidentified by Matrix Assisted Laser Desorption/Ionisation Time of Flight Mass Spectrometry (MALDI-TOF MS) as *Trichosporon ovoides* which was later identified by molecular sequencing as *Candida krusei*.

Keywords: *Candida* species, Fungemia, Haematological malignancy

CASE REPORT

A 10-year-old male with T-cell ALL, who had received high-dose consolidation chemotherapy (HR3 block of ALL IC-BFM 2009 protocol) [1], was admitted on day 11 of chemotherapy cycle with fever and non-productive cough. An informed consent was obtained from the patient. On physical examination, the patient was febrile (100.4°F/38°C) with a heart rate of 120 beats/min, respiratory rate of 24/min, and blood pressure of 70/40 mmHg. His Total Leukocyte Count (TLC) was 480/ μ L and Platelet Count was 11000/ μ L. There was no family history for any such similar illness. Blood culture sample was sent from the indwelling Peripherally Inserted Central Catheter (PICC) and empiric intravenous antibiotics were started (Piperacillin-Tazobactam, Teicoplanin and Amikacin) for febrile neutropenia. His cough and fever worsened and TLC dropped from 250 μ L/on day 12 to 103/ μ L on day 13. In view of the substantial decline of the white blood cells, the antibiotic regimen was escalated to Meropenem (1 g IV q8hr) and antifungal therapy was also started with liposomal Amphotericin B (3 mg/kg/day). His blood culture beeped positive on day 14 after which the PICC line was removed. Direct gram stain from the blood culture bottle revealed gram-variable budding yeast cells [Table/Fig-1]. Within 24 hours of subculture, white creamy colonies were obtained on blood agar and Sabouraud's Dextrose Agar (SDA) (Hi Media India) [Table/Fig-2]. Germ tube test was performed using *C. albicans* ATCC 90028 as control and demonstrated negative results for germ tube production. It was further identified as *Trichosporon ovoides* by MALDI-TOF MS (Bruker Daltonics, Bremen, Germany) with a Confidence Interval (CI) of 1.41 by direct formic acid extraction. Antifungal susceptibility was performed on VITEK 2 (Biomerieux, Craaponne, France). It was found resistant to Fluconazole (MIC \geq 64 μ g/mL), Flucytosine (\geq 64 μ g/mL), Amphotericin-B (\geq 1 μ g/mL) and was found susceptible to Voriconazole (MIC \leq 0.25 μ g/mL). Antifungal therapy was changed from Amphotericin B to Voriconazole (6 mg/kg/day q12h on day 1, followed by 4 mg/kg q12h for 7 days). He became afebrile on Day +17, and was discharged in stable condition.

However, in order to confirm the identity of the isolate, Internal Transcribed Spacer (ITS) regions (ITS1-5.8S-ITS2) were amplified using ITS1 (5'-TCCGTAGGT GAACCTGCGG-3) and ITS4 (5'-TCCTCCGCTT ATTGATATGC-3') by National Culture Collection of



[Table/Fig-1]: Gram stain showing gram-variable budding yeast cells.



[Table/Fig-2]: White, creamy pasty colonies seen on sabouraud's dextrose agar.

Pathogenic Fungi (NCCPF) PGI, Chandigarh, India. Comparison of the nucleotide sequence of the isolate obtained with the Gene Bank database using the Basic Local Alignment Search Tool (BLAST) algorithm yielded 100% homology with the ex-type strain of *C. krusei*.

The patient came for follow-up two weeks later, when a repeat blood culture was taken which came out to be sterile and proved that he responded to Voriconazole therapy.

DISCUSSION

In United States, *Candida* spp. are considered as the third leading pathogen which is responsible for BSI. In India *Candida* spp. is the fourth leading cause of BSI in hospitalised patients, with an associated mortality of 40-50% [2]. Although candidemia is not as prevalent as bacteraemia, it is associated with high morbidity and mortality in both immunocompromised and immunocompetent critically ill patients [3]. A worldwide systematic review of *Candida* BSI prevalence found that *Candida krusei* constantly made up 1%-4% of infections regardless of geographic location, whereas two studies reported proportions of 8.5% and 10.6% in Finland and France respectively [4].

Risk of *Candida* infection is high when it is associated with risk factors like febrile neutropenia, chemotherapy, central venous catheters, steroid therapy, ventilators, urinary catheterisation, total parenteral nutrition, HIV infection, prolonged hospital stay, haematological and gastric malignancy, prior azole use, prior monoclonal antibody use and prior β -lactam/ β -lactamase inhibitor use [5,6].

C. krusei has emerged as a notable pathogen, especially in immunocompromised patient groups in nosocomial settings. Widespread use of Triazole in these patients has contributed to a selective increase in *C. krusei* infection. In haematological malignancies, patient is given a cocktail of antibacterial, antifungal agents for prophylaxis. In a study conducted in Lebanon, increased consumption of antifungals by haematology department was observed. They also noticed that NAC spp. constituted 59% of all BSI with most common being *Candida krusei* [7]. In another study conducted by Abbas J et al., 49 patients (86%) with prior antifungal exposure were found to have colonisation with *Candida krusei* [8]. Presence of central venous catheters allows formation of biofilm by *C. albicans* followed by *C. krusei* which are known to be a very high biofilm producer with predilection to mucosal surfaces and respiratory tract compared to other NAC. This biofilm confers higher resistance to antifungals. Quantification of biofilm can be done by XTT assay (tetrazolium salt reduction) assay where there is reduction of XTT to formazan.

Recently, there is a shift from *C. albicans* to NAC spp. as the predominant infecting species in patients with cancer who had candidemia. Among the factors that have been proposed to explain this shift in the distribution of the *Candida* spp. responsible for candidemia is the prevalent use of Fluconazole and Miconazole as a prophylactic antifungal agent, especially in patients with haematologic malignancies and recipients of bone marrow transplantation [9]. Fluconazole resistance by *C. krusei* is 96.6% through various mechanisms like increased ABC transporter expression, low affinity of Fluconazole to ergosterol-11, aneuploidy [10].

Regardless of the types of antifungal therapy used, the inferior response in patients with haematologic malignancies may cause by the severity of the infection and the status of the underlying disease. The other reason which is immunity against NAC is poorly understood. *Candida* in blood may disseminate into brain by crossing blood brain barrier and phagocytosed by microglial cells. In *Candida krusei*, yeast transform into pseudohyphae in microglial cells, and escape immunity (nitric oxide stress of phagocytes) by vomocytosis [11]. This morphological transformation is not observed in other NAC spp.

Patients with haematologic malignancies are found to be admitted to the ICU more frequently, were neutropenic during the course of

their candidemia, and were associated with poor outcome and high mortality [12]. In addition, the overall response was found to be better in patients who did not receive prior antifungal prophylaxis regardless of the treatment modality [9].

The use of MALDI-TOF MS has revolutionised the diagnosis of fungal infections as it has enabled us to identify rare and non-sporulating types of fungi. But in this case, it misidentified a simple yeast like colony i.e., *Candida krusei* as *Trichosporon ovoides*. This highlights the fact that MALDI-TOF MS cannot be taken as the gold standard for identification of fungal isolates and proves that molecular sequencing should be done, if possible to confirm the MALDI-TOF MS findings. In this case, the diagnosis could have missed as we relied heavily on the MALDI-TOF MS finding and started the patient on voriconazole thinking of *Trichosporon ovoides* as the causative fungi. Correct identification is of utmost important as antifungal susceptibilities are different for different fungi and it helps to start the right treatment for the right patient.

CONCLUSION(S)

This case highlights the need for constant lookout for Non-*albicans* candidemia especially in immunocompromised patients. In this case, the presence of central line along with haematological malignancy was purported to cause candidemia. It was also concurred from this case that MALDI-TOF MS cannot be relied upon totally for the confirmation of such yeast like species and molecular sequencing should always be performed before the initiation of antifungal therapy especially in such group of patients.

REFERENCES

- [1] Chemotherapy regimens for Pediatric ALL. Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines Geneva, 29 September to 3 October 2008. https://www.who.int/selection_medicines/committees/subcommittee/2/cytotoxic_review.pdf.
- [2] Duggal SD, Jena PP, Gur R, Kumar A, Rongpharpi SR, Pandey M, et al. Recurring events of *Candida krusei* septicemia: First report from an ICU. *Journal of Mycology*. 2015;2015:721424.
- [3] Deorukhkar SC, Saini S. Echinocandin susceptibility profile of fluconazole resistant *Candida* species isolated from blood stream infections. *Infectious Disorders- Drug Targets*. 2016;16(1):63-68.
- [4] Falagas ME, Roussos N, Vardakas KZ. Relative frequency of *albicans* and the various non-*albicans Candida* spp among candidemia isolates from inpatients in various parts of the world: A systematic review. *Int J Infect Dis*. 2010;14(11):e954-66.
- [5] Kronen R, Hsueh K, Lin C, Powderly WG, Spec A. Creation and assessment of a clinical predictive calculator and mortality associated with *Candida krusei* bloodstream infections. In *Open Forum Infectious Diseases*. 2018;5(2):ofx253.
- [6] Giri S, Kindo AJ. A review of *Candida* species causing blood stream infection. *Indian J Med Microbiol*. 2012;30(3):270-78.
- [7] Awad L, Tamim H, Abdallah D, Salameh M, Mugharbil A, Jisr T, et al. Correlation between antifungal consumption and the distribution of *Candida* species in different hospital departments of a Lebanese medical Centre. *BMC Infectious Diseases*. 2018;18(1):589.
- [8] Abbas J, Bodey GP, Hanna HA, Mardani M, Girgawy E, Abi-Said D, et al. *Candida krusei* fungemia: An escalating serious infection in immunocompromised patients. *Archives of Internal Medicine*. 2000;160(17):2659-64.
- [9] Hachem R, Hsueh H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: *Candida glabrata* and *Candida krusei* as the leading causes of candidemia in hematologic malignancy. *Cancer: Interdisciplinary International Journal of the American Cancer Society*. 2008;112(11):2493-99.
- [10] Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in *Candida albicans* and emerging Non-*albicans Candida* species. *Front Microbiol*. 2017;7:2173.
- [11] Sanches MD, Mimura LA, Oliveira LR, Ishikawa LL, Garces HG, Bagagli E, et al. Differential behaviour of Non-*albicans Candida* species in the central nervous system of immunocompetent and immunosuppressed mice. *Frontiers in microbiology*. *Front Microbiol*. 2018;9:2968.
- [12] Maqsood S, Badar F, Hameed A. Characteristics and outcomes of patients with haematological malignancies admitted for intensive care- A single centre experience. *Asian Pac J Cancer Prev*. 2017;18(7):1833-37.

PARTICULARS OF CONTRIBUTORS:

1. Assistant Professor, Department of Microbiology, AIIMS, Rishikesh, Uttarakhand, India.
2. Assistant Professor, Department of Laboratory Medicine, AIIMS, New Delhi, India.
3. Additional Professor, Department of Medical Oncology and Haematology, AIIMS, Rishikesh, Uttarakhand, India.
4. Senior Resident, Department of Medical Oncology and Haematology, AIIMS, Rishikesh, Uttarakhand, India.
5. Professor, Department of Microbiology, AIIMS, Rishikesh, Uttarakhand, India.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Dr. Aroop Mohanty,
Assistant Professor, Department of Microbiology, AIIMS Rishikesh, Veerbhadra Marg,
Rishikesh-249203, Uttarakhand, India.
E-mail: aroopmohanty7785@yahoo.com

PLAGIARISM CHECKING METHODS: [\[Jain H et al.\]](#)

- Plagiarism X-checker: Mar 11, 2020
- Manual Googling: Apr 21, 2020
- iThenticate Software: Apr 27, 2020 (11%)

ETYMOLOGY: Author Origin**AUTHOR DECLARATION:**

- Financial or Other Competing Interests: None
- Was informed consent obtained from the subjects involved in the study? Yes
- For any images presented appropriate consent has been obtained from the subjects. NA

Date of Submission: **Mar 11, 2020**Date of Peer Review: **Apr 06, 2020**Date of Acceptance: **Apr 22, 2020**Date of Publishing: **May 01, 2020**